Evidence map›Paper›PMID 26598521›Full record

ArticleThe Journal of biological chemistry2016

Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis.

Wan Yee Leong, Hong Guo, Ou Ma, Hui Huang, Alan B Cantor, Alan D Friedman

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. RUNX1 Dosage in Development and Cancer.Molecules and cells · 2020
    Review
  8. Review
  9. Article
  10. RUNX1 cooperates with FLT3-ITD to induce leukemia.The Journal of experimental medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wan Yee LeongFrom the Division of Pediatric Oncology, The Johns Hopkins University, Baltimore, Maryland 21231 and.
Hong GuoFrom the Division of Pediatric Oncology, The Johns Hopkins University, Baltimore, Maryland 21231 and.
Ou MaFrom the Division of Pediatric Oncology, The Johns Hopkins University, Baltimore, Maryland 21231 and.
Hui Huangthe Department of Pediatric Hematology-Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
Alan B Cantorthe Department of Pediatric Hematology-Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
Alan D FriedmanFrom the Division of Pediatric Oncology, The Johns Hopkins University, Baltimore, Maryland 21231 and afriedm2@jhmi.edu.
Johns Hopkins University · USDana-Farber Cancer Institute · USHarvard University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Basic and Translational Research of iPSC-Based hematologic and Vascular TherapiesU01HL099775 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI FRIEDMAN, ALAN D · 2009 to 2015
$8.4M
Proteomic Approach to Further Understanding the Role of*R01HL082952 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI CANTOR, ALAN B. · 2005 to 2008
$1.3M
NCI NIH HHS P30 CA006973NHLBI NIH HHS R01 HL082952NHLBI NIH HHS U01 HL099775
6 · The paper itself

Abstract

Src phosphorylates Runx1 on one central and four C-terminal tyrosines. We find that activated Src synergizes with Runx1 to activate a Runx1 luciferase reporter. Mutation of the four Runx1 C-terminal tyrosines to aspartate or glutamate to mimic phosphorylation increases trans-activation of the reporter in 293T cells and allows induction of Cebpa or Pu.1 mRNAs in 32Dcl3 myeloid cells, whereas mutation of these residues to phenylalanine to prevent phosphorylation obviates these effects. Three mechanisms contribute to increased Runx1 activity upon tyrosine modification as follows: increased stability, reduced histone deacetylase (HDAC) interaction, and increased DNA binding. Mutation of the five modified Runx1 tyrosines to aspartate markedly reduced co-immunoprecipitation with HDAC1 and HDAC3, markedly increased stability in cycloheximide or in the presence of co-expressed Cdh1, an E3 ubiquitin ligase coactivator, with reduced ubiquitination, and allowed DNA-binding in gel shift assay similar to wild-type Runx1. In contrast, mutation of these residues to phenylalanine modestly increased HDAC interaction, modestly reduced stability, and markedly reduced DNA binding in gel shift assays and as assessed by chromatin immunoprecipitation with the -14-kb Pu.1 or +37-kb Cebpa enhancers after stable expression in 32Dcl3 cells. Affinity for CBFβ, the Runx1 DNA-binding partner, was not affected by these tyrosine modifications, and in vitro translated CBFβ markedly increased DNA affinity of both the translated phenylalanine and aspartate Runx1 variants. Finally, further supporting a positive role for Runx1 tyrosine phosphorylation during granulopoiesis, mutation of the five Src-modified residues to aspartate but not phenylalanine allows Runx1 to increase Cebpa and granulocyte colony formation by Runx1-deleted murine marrow.

Indexed as

HematopoiesisTranscriptional ActivationAnimalsCore Binding Factor Alpha 2 SubunitDNAGranulocytesHistone DeacetylasesHumansMicePhosphorylationPhosphotyrosineProtein BindingProtein Stabilitysrc-Family KinasesCore Binding Factor Alpha 2 SubunitDNAHistone DeacetylasesPhosphotyrosinesrc-Family Kinaseshematopoiesishistone deacetylase (HDAC)myeloid cellRunx1Srctranscription factortyrosine kinase

Identifiers

PMID26598521
PMCPMC4705401
OpenAlexW2231217801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.